Reimbursement and coding for biosimilars: how billing works

Have you ever wondered why a biologic drug costs one amount in the pharmacy but gets billed differently to insurance? The world of medical billing is complex, but nothing confuses providers quite like biosimilars billing is a specialized process governing how similar versions of biologic drugs are billed and paid for under Medicare Part B.. If you manage a clinic or handle claims, you know that a single wrong code can mean a denied claim and lost revenue. Today, we are breaking down exactly how this system functions, from the codes you type to the math behind the payment.

Understanding Biosimilars vs. Generics

Before we talk about money, we need to clarify what we are actually billing for. Many people mix up biosimilars with generic drugs. They sound similar, but they are fundamentally different in the eyes of the regulator. A generic drug is a carbon copy of a small molecule drug. It works exactly the same way and is chemically identical. Biosimilars, however, are large molecule drugs made from living cells. They are highly similar to an original reference product, but they are not exact copies.

This distinction matters for billing because Centers for Medicare & Medicaid Services (CMS) is the federal agency that manages Medicare and Medicaid programs and sets reimbursement policies. treats them differently. Generics often share National Drug Codes (NDCs) in a way that makes them interchangeable without much fuss. Biosimilars require specific tracking. This is why you cannot simply use the code for the original brand name drug when you administer a biosimilar. You need the specific code assigned to that biosimilar product to ensure you get paid correctly.

The Coding System: HCPCS and J-Codes

When you submit a claim for a drug administered in a clinic, you use the Healthcare Common Procedure Coding System. This is known as HCPCS. For drugs like biosimilars, you will mostly encounter J-codes. These are Level II HCPCS codes that identify specific drugs and biologicals. In the past, CMS grouped all biosimilars for a specific reference product under one single code. This created a blended rate that didn't reflect the actual cost of the specific drug you gave the patient.

That changed in 2018. Now, each FDA-approved biosimilar gets its own unique product-specific code. You might see a temporary Q-code assigned when a drug first launches, which later converts to a permanent J-code. For example, if you are administering an infliximab biosimilar, you need to know if you are using the specific code for Inflectra or Renflexis. Using the wrong code leads to immediate denial. The system requires you to verify the correct code against the quarterly updates from CMS. This ensures that the payment rate matches the specific product's Average Selling Price.

How Reimbursement Math Works

Let's get into the numbers. You want to know how much you will get paid for administering these drugs. The standard formula under Medicare Part B is the component of Medicare that covers physician-administered drugs and outpatient services. is 100% of the Average Selling Price (ASP) plus 6% of the reference product's ASP. This is often called the 106% rule. However, for biosimilars, the math has a specific twist. You get 100% of the biosimilar's own ASP, but the 6% add-on is calculated based on the reference product's ASP, not the biosimilar's.

Why does this matter? Imagine the reference product costs $2,500 per dose. The biosimilar costs $2,000. You get paid $2,000 for the drug itself. Then you get the 6% add-on. That 6% is calculated on the $2,500, not the $2,000. So you get $150 in add-on revenue. If the add-on were based on the biosimilar price, you would only get $120. This structure was designed to encourage providers to use biosimilars without losing revenue, but critics argue it still favors the more expensive reference product because the absolute dollar amount of the add-on is higher for the brand.

For the very first biosimilar to enter a market, there is a transition period. If there isn't enough sales data to calculate an ASP yet, CMS pays 106% of the Wholesale Acquisition Cost (WAC) for the first six months. After that, they switch to the ASP-based calculation. Subsequent biosimilars for the same drug skip this transition and go straight to the ASP rate. This means billing staff need to check if the drug is in its transition phase to ensure they aren't undercoding.

Historical Changes: 2016 to 2018 Shift

It is helpful to understand where we came from to appreciate the current rules. In 2016, CMS started the biosimilar reimbursement program. They used a blended code system. All biosimilars for Remicade, for instance, shared one code. The payment rate was a weighted average of all the biosimilars plus the reference product. This created a problem known as the "free rider" effect. If a new, cheaper biosimilar entered the market, it lowered the average payment for everyone, including the existing biosimilars. Manufacturers didn't want to lower their prices if it hurt their competitors' revenue.

By 2018, CMS realized this was slowing down market entry. They switched to the product-specific coding we use today. This change meant every biosimilar had its own lane. Your reimbursement depended only on your product's ASP, not your competitor's. This was a huge win for market competition. However, it also increased the administrative burden on providers. You now had to learn and manage multiple codes for what was previously one code. Practices reported spending 40 to 60 hours training staff during this transition to avoid claim denials.

Common Pitfalls and Modifiers

Even with the current system, mistakes happen. One of the biggest recent changes involves the JZ modifier. As of July 1, 2023, CMS mandated the use of the JZ modifier for infliximab and biosimilar claims where there are no discarded amounts. If you administer the full vial and throw nothing away, you must add JZ. If you do not, the claim might be denied or adjusted. This applies specifically to drugs where waste tracking is critical.

Another common issue is using outdated codes. CMS updates the Physician Fee Schedule quarterly. If you are billing for a drug launched late last year, the code might have changed from a temporary Q-code to a permanent J-code. If you submit a claim with the old code, the system rejects it. Successful practices implement a dual verification system. The pharmacy staff checks the administered product against the billing code before the claim goes out. This simple step reduces error rates significantly. Manufacturers also help here. Companies like Fresenius Kabi provide coding guides that 87% of providers found helpful in reducing errors.

Future Outlook and Policy Changes

Looking ahead, the system is not static. The Medicare Payment Advisory Commission (MedPAC) has been pushing for changes. They are considering a "consolidated billing" approach. This would blend coding and payment for all biologics and biosimilars again, but with a twist. It would establish a Least Costly Alternative (LCA) payment policy. This means reimbursement would equal 106% of the volume-weighted average ASP across all products in the class, regardless of which one you used.

This is a hot topic for 2025 and 2026. If CMS adopts LCA policies for high-utilization biosimilars, it could change how you bill again. The goal is to save Medicare money by incentivizing the use of the cheapest option. However, some analysts worry this might reduce the revenue for providers who prefer the reference product. Currently, the US biosimilar market share is around 35% for mature products, while Europe sees 75-85%. The reimbursement structure is a big reason for this gap. As CMS monitors these trends, they may adjust the 6% add-on structure to make biosimilars more financially attractive for clinics.

Practical Steps for Providers

To navigate this successfully, you need a routine. First, subscribe to CMS updates for the Physician Fee Schedule. Do not rely on memory for codes. Second, train your billing staff on the JZ modifier requirements. Make sure they understand when waste occurs and when it does not. Third, use manufacturer resources. Most biosimilar makers have dedicated support lines for billing questions. Finally, audit your claims monthly. Look for denials related to code mismatches. If you see a pattern, adjust your workflow immediately. The goal is clean claims that get paid the first time.